Q3 EPS Forecast for Aura Biosciences Lowered by Analyst

Aura Biosciences, Inc. (NASDAQ:AURA) – HC Wainwright lowered their Q3 2025 EPS estimates for Aura Biosciences in a report issued on Wednesday, August 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.47) for the quarter, down from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.15) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($1.70) EPS and FY2029 earnings at ($1.32) EPS.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $19.00 price target on shares of Aura Biosciences in a research report on Friday, May 23rd. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $22.00.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $6.72 on Friday. Aura Biosciences has a 52 week low of $4.34 and a 52 week high of $12.38. The firm has a market cap of $417.45 million, a price-to-earnings ratio of -3.43 and a beta of 0.46. The firm’s 50-day simple moving average is $6.62 and its 200 day simple moving average is $6.53.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of AURA. Tower Research Capital LLC TRC lifted its holdings in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after acquiring an additional 2,104 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Aura Biosciences by 8.3% in the first quarter. American Century Companies Inc. now owns 51,657 shares of the company’s stock worth $303,000 after acquiring an additional 3,956 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after acquiring an additional 3,972 shares during the last quarter. Acorn Capital Advisors LLC lifted its holdings in shares of Aura Biosciences by 0.9% in the second quarter. Acorn Capital Advisors LLC now owns 595,744 shares of the company’s stock worth $3,729,000 after acquiring an additional 5,236 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Aura Biosciences by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after acquiring an additional 5,930 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.